Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Michelina Cairo, MD from Texas Oncology speaks about ESMO 2021 Abstract LBA1 – Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in...

Michelina Cairo, MD from Texas Oncology speaks about ESMO 2021 Abstract LBA1 – Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in...

The addition of 2 years of abiraterone acetate plus prednisolone (AAP) to androgen-deprivation therapy improves metastasis-free survival and overall survival compared with androgen-deprivation therapy...

Vimseltinib was well tolerated and demonstrated promising preliminary efficacy in patients with tenosynovial giant cell tumors whose tumors are not amendable to surgical resection,...

Retroperitoneal surgery for patients with sarcoma requires nuanced decision making that incorporates technical aspects of resection, as well as patient-related and tumor-related factors, according...

From Total Health’s 2021 ESMO Virtual Review on October 23-24, 2021, we bring you a session on clinical trial accrual presented by Dr. Arturo...

Meredith A. McKean, MD, MPH, Sarah Cannon Research Institute, Nashville, TN, discusses the efficacy, safety and pharmacokinetic and pharmacodynamic...

Longer follow-up data from the phase III CheckMate 649 trial support the use of nivolumab plus chemotherapy as a new standard first-line regimen in...